| F-star Therapeutics is a clinical-stage biopharmaceutical company. Co. is engaged in the discovery and development of therapeutics for the treatment of a range of cancers and inflammatory diseases. Co.'s STING (STimulator of INterferon Genes) product portfolio include STING agonist clinical program in oncology, STING antagonist compounds for inflammatory diseases, and STING agonist antibody drug conjugate program for oncology. Co. is developing its SB 11285, as an immunotherapeutic cyclic dinucleotide for the treatment of selected cancers. Co. is also exploring the use of its STING antagonist compounds for the treatment of certain autoimmune and inflammatory diseases. The FSTX YTD return is shown above.
The YTD Return on the FSTX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FSTX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FSTX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.